Streetbeat News

Stock Prices

AREB

CTVA

LEO

MULN

During Friday's session, 157 stocks hit new 52-week lows. Among the notable companies were Corteva, American Rebel Holdings, Mullen Automotive, and BNY Mellon Strategic. The stocks that created new 52-week lows on Friday included Avangrid, SolarEdge Technologies, Etsy, UGI, Concentrix, Hawaiian Electric Indus, Equity Commonwealth, Forward Air, Cracker Barrel Old, Petco Health and Wellness, JinkoSolar Holding Co, Olaplex Hldgs, Frontier Group Holdings, Impinj, Safehold, Monro, 3D Sys, TDCX, Everbridge, Silk Road Medical, Cassava Sciences, 23andMe Holding, Wolverine World Wide, Avidity Biosciences, Boston Omaha, John Hancock Premium Div, BioLife Solns, Seres Therapeutics, American Well, Materialise, BNY Mellon Strategic, Southland Holdings, Funko, Fate Therapeutics, Citizens Financial Servs, American Lithium, Emergent BioSolutions, PetMed Express, Sutro Biopharma, Hippo Holdings, Largo, Omega Therapeutics, System1, Benson Hill, Eaton Vance Municipal, Vor Biopharma, Star Hldgs, Origin Mat, Joint, NanoString Technologies, Codexis, ContextLogic, Akoustis Technologies, Cano Health, GeneDx Hldgs, Electrovaya, Kezar Life Sciences, ProPhase Labs, Alaunos Therapeutics, Chimerix, Electriq Power Holdings, DZS, Streamline Health Solns, Eargo, Intercure, Prime Number Acquisition, REE Automotive, TD Hldgs, Carmell Therapeutics, Neuronetics, Kaixin Auto Hldgs, Crown Crafts, Airgain, Ohmyhome, Singular Genomics Sys, First Seacoast Bancorp, Sarcos Technology, Coya Therapeutics, Otonomo Technologies, CareCloud, Aterian, PAVmed, Orgenesis, CalAmp, Imperial Ptrl, Fitell, LQR House, Iridex, OMNIQ, Safeguard Scientifics, Lichen China, Origin Agritech, Atreca, Sunlight Finl Hldgs, Yunji, MediaCo Holding, Trio Petroleum, Cineverse, Lucy Scientific Discovery, Remark Hldgs, Shuttle Pharmaceuticals, Hempacco, Finch Therapeutics Gr, Visionary Education Tech, Marpai, Ontrak, Nogin, Adamis Pharmaceuticals, China Jo-Jo Drugstores, ABVC BioPharma, Fangdd Network Group, SeaStar Medical Holding, Yoshiharu Global, Universe Pharmaceuticals, Redhill Biopharma, Jiuzi Hldgs, Power REIT, Soligenix, Eightco Holdings, JanOne, Avalo Therapeutics, Yield10 Bioscience, Aditxt, Salarius Pharmaceuticals, China Pharma Holding, OpGen, Akanda, Harbor Custom Dev, Biocept, NeuBase Therapeutics, Ucommune International, INVO Bioscience, Esports Entertainment, American Rebel Holdings.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

VVOS

Vivos Therapeutics (NASDAQ:VVOS) is set to release its latest quarterly earnings report on August 14, 2023. Analysts estimate an earnings per share (EPS) of $-0.14. The company's past performance shows a trend of missing EPS estimates and subsequent drops in share price. The stock is currently trading at $0.3431, down 76.23% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

EGLX

Enthusiast Gaming Hldgs (NASDAQ:EGLX) is set to release its quarterly earnings report on Monday, 2023-08-14. Analysts estimate an earnings per share (EPS) of $-0.05. The company's past performance shows a pattern of share price drops following earnings reports. The stock is currently trading at $0.5233, down 72.82% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

NGS

Natural Gas Services Gr (NYSE:NGS) is set to release its latest quarterly earnings report on August 14, 2023. Analysts estimate an EPS of $-0.02. The company's past performance shows a mixed impact on the share price post-earnings release. The stock is currently trading at $10.13 and has seen a 3.58% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

TMC

TMC Metals is set to release its latest quarterly earnings report on August 14, 2023. Analysts estimate an earnings per share (EPS) of $-0.12. The company's past performance shows a pattern of share price drops following earnings reports, despite beating EPS estimates. The company's shares were trading at $1.2 as of August 10, with a 10.05% increase over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

OMQS

OMNIQ (NASDAQ:OMQS) is set to release its latest quarterly earnings report on August 14, 2023. Analysts estimate an earnings per share (EPS) of $-0.35. The company's past performance shows a trend of missing EPS estimates, which has often resulted in a drop in share price. Shares of OMNIQ are currently trading at $2.99 and have seen a 66.01% decrease over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

A significant bearish stance has been taken on Home Depot (NYSE:HD) as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 29% bullish and 70% bearish. The price range targeted by these traders for Home Depot over the last 3 months is from $300.0 to $340.0. Various experts have given different ratings and price targets for Home Depot.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:00 pm

SNOW

A significant bearish stance has been taken on Snowflake (NYSE:SNOW) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is split, with 40% bullish and 60% bearish. Whales have been targeting a price range from $100.0 to $180.0 for Snowflake over the last 3 months. Exane BNP Paribas, Oppenheimer, and Scotiabank have given price targets of $173, $220, and $213 respectively.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:00 pm

FDX

FedEx (NYSE:FDX) has received various analyst ratings in the last quarter, with 4 bullish, 6 somewhat bullish, and 3 indifferent. The average 12-month price target for FedEx, according to 13 analysts, is $262.38, with a high of $290.00 and a low of $186.00. This average price target has increased by 6.23% over the past month.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:00 pm

STRO

Analysts have provided bullish and somewhat bullish ratings for Sutro Biopharma (NASDAQ:STRO) in the last quarter. According to 6 analysts offering 12-month price targets in the last 3 months, Sutro Biopharma has an average price target of $15.83, a 20.85% decrease from the previous average price target of $20.00.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:00 pm